Skip to content

The Efficacy and Safety of Heparin to Prevent Embolic Events Related to Transradial Cerebral Angiography

The Efficacy and Safety of Heparin to Prevent Embolic Events Related to Transradial Cerebral Angiography

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080902
Enrollment
Unknown
Registered
2024-02-18
Start date
2024-03-01
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embolic Events Related to Transradial Cerebral Angiography

Interventions

Heparinization and continuous infusion of heparin group:Injection of intra-arterial heparin (3000 U) through the radial artery sheath, followed by continuously infusing heparin saline (25 U/kg/h) thro
Heparinization group:Injection of intra-arterial heparin (3000 U) through the radial artery sheath
Control group:Without any heparinization

Sponsors

Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age =18 years old; (2) Patients undergoing transradial cerebral angiography; (3) No abnormalities were found on DWI within 1 month before transradial cerebral angiography; (4) The subject or legal representative signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Any active bleeding or recent bleeding (gastrointestinal tract, urinary tract bleeding, etc.) within 30 days before transradial cerebral angiography; (2) Solid organ surgery and biopsy within 14 days before transradial cerebral angiography; (3) Platelet count <100×10^9/L; (4) Allergy or contraindication to heparin and iodine contrast agents; (5) History of heparin-related thrombocytopenia; (6) Patients undergoing any anticoagulation therapy; (7) Clear bleeding tendency, coagulation system diseases, severe liver disease, severe kidney disease, severe acute infectious diseases (such as infective endocarditis, active tuberculosis, etc.), malignant tumors, and pregnant or breastfeeding women; (8) Patients who are judged by the researcher to be unfit to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Proportion of embolic events related to transradial cerebral angiography;

Secondary

MeasureTime frame
Proportion of operative success;Operation time;Contrast medium;Fluoroscopy time;

Countries

China

Contacts

Public ContactXiang Luo

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Medical College, Huazhong University of Science and Technology

flydottjh@163.com+86 133 4989 3413

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 2, 2026